retatrutide retatrutide Retatrutide: Fat Loss, Liver Health & Muscle Care Retatrutide: The triple-action peptide revolutionizing

2025 Dec 1;329(6):G680-G695

Intellias NTLA-2001, being developed along with partner Regeneron for the genetic liver disease transthyretin (ATTR) amyloidosis cardiomyopathy, is expected to enter Phase III by the end of this year, Intellia announced

The drug was Novo Nordisks Wegovy, which had recently picked up a Food and Drug Administration approval for use as a treatment in heart disease

Nonsteroidal MRAs (nsMRA) supposedly selectively block this pathway, suppressing pro-inflammatory and pro-fibrotic signaling and slow structural kidney damage beyond their modest hemodynamic effects

Which company is identified as a leading player in the GLP-1 Companion Products Market

Investigations: ECG & ECHO : No RWMA, LV EF: 55%, Trivial TR CT Brain Large ICH in the left temporoparietal region with mass effect Midline shift Diffuse cerebral edema Diagnosis: Left Gangliocapsular bleed (ICH) with mass effect and IVH with obstructive hydrocephalus Systemic Hypertension Case Presentation: Day 1 The patient underwent an emergency Left Frontotemporoparietal (FTP) decompressive craniectomy with evacuation of ICH and tracheostomy under general anesthesia